Musculoskeletal Disorders, Pain Medication, and in-Hospital Mortality among Patients with COVID-19 in South Korea: A Population-Based Cohort Study
Tak-Kyu Oh, In-Ae Song, Joon Lee, Woosik Eom, Young-Tae Jeon
International Journal of Environmental Research and Public Health, doi:10.3390/ijerph18136804
We aimed to investigate whether comorbid musculoskeletal disorders (MSD)s and pain medication use was associated with in-hospital mortality among patients with coronavirus disease 2019 . Adult patients (≥20 years old) with a positive COVID-19 diagnosis until 5 June 2020 were included in this study, based on the National Health Insurance COVID-19 database in South Korea. MSDs included osteoarthritis, neck pain, lower back pain, rheumatoid arthritis, and others, while pain medication included paracetamol, gabapentin, pregabalin, glucocorticoid, nonsteroidal anti-inflammatory drugs (NSAIDs), opioids (strong and weak opioids), and benzodiazepine. Primary endpoint was in-hospital mortality. A total of 7713 patients with COVID-19 were included, and in-hospital mortality was observed in 248 (3.2%) patients. In multivariate logistic regression analysis, no MSDs (p > 0.05) were significantly associated with in-hospital mortality. However, in-hospital mortality was 12.73 times higher in users of strong opioids (odds ratio: 12.73, 95% confidence interval: 2.44-16.64; p = 0.002), while use of paracetamol (p = 0.973), gabapentin or pregabalin (p = 0.424), glucocorticoid (p = 0.673), NSAIDs (p = 0.979), weak opioids (p = 0.876), and benzodiazepine (p = 0.324) was not associated with in-hospital mortality. In South Korea, underlying MSDs were not associated with increased in-hospital mortality among patients with COVID-19. However, use of strong opioids was significantly associated with increased in-hospital mortality among the patients.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10 .3390/ijerph18136804/s1, Table S1 : ICD-10 codes and Table S2 : The ICD-10 codes used by comorbidity to compute the Charlson comorbidity index. Informed Consent Statement: Informed consent was waived by the IRB, as the analyses were performed retrospectively using anonymized data derived from the South Korean NHIS database.
Conflicts of Interest: The authors declare no conflict of interest.
References
Briggs, Woolf, Dreinhöfer, Homb, Hoy et al., Reducing the global burden of musculoskeletal conditions, Bull. World Heal. Organ,
doi:10.2471/BLT.17.204891Dagan, Barda, Kepten, Miron, Perchik et al., BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting, N. Engl. J. Med,
doi:10.1056/NEJMoa2101765Diasso, Birke, Nielsen, Main, Højsted et al., The effects of long-term opioid treatment on the immune system in chronic non-cancer pain patients: A systematic review, Eur. J. Pain,
doi:10.1002/ejp.1506Elm, Altman, Egger, Pocock, Gøtzsche et al., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies, Ann. Intern. Med,
doi:10.7326/0003-4819-147-8-200710160-00010Flint, Janowitz, Connell, Roberts, Denton et al., Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity, Cell Metab,
doi:10.1016/j.cmet.2016.10.010Fredi, Cavazzana, Moschetti, Andreoli, Franceschini et al., COVID-19 in patients with rheumatic diseases in northern Italy: A single-centre observational and case-control study, Lancet Rheumatol,
doi:10.1016/S2665-9913(20)30169-7Generaal, Vogelzangs, Macfarlane, Geenen, Smit et al., Basal inflammation and innate immune response in chronic multisite musculoskeletal pain, Pain,
doi:10.1016/j.pain.2014.05.007Greenland, Mansournia, Altman, Sparse data bias: A problem hiding in plain sight, BMJ,
doi:10.1136/bmj.i1981Haberman, Axelrad, Chen, Castillo, Yan et al., Covid-19 in Immune-Mediated Inflammatory Diseases-Case Series from New York, N. Engl. J. Med,
doi:10.1056/NEJMc2009567Haberman, Castillo, Chen, Yan, Ramirez et al., COVID-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes, Arthritis Rheumatol,
doi:10.1002/art.41456Kim, Fine, Li, Kimmel, Ngo et al., Disparities in United States hospitalizations for serious infections in patients with and without opioid use disorder: A nationwide observational study, PLoS Med,
doi:10.1371/journal.pmed.1003247Mackinnon, Socías, Bardwell, COVID-19 and overdose prevention: Challenges and opportunities for clinical practice in housing settings, J. Subst. Abus Treat,
doi:10.1016/j.jsat.2020.108153Manuel, Estabrook, The American Society of Transplantation Infectious Diseases Community of Practice. RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice, Clin. Transplant,
doi:10.1111/ctr.13511Oh, Jeon, Choi, Trends in chronic opioid use and association with five-year survival in South Korea: A populationbased cohort study, Br. J. Anaesth,
doi:10.1016/j.bja.2019.08.012Oh, Song, Trends in long-term glucocorticoid use and risk of 5-year mortality: A historical cohort study in South Korea, Endocrine,
doi:10.1007/s12020-020-02382-6Pereira, Lawlor, Vigano, Dorgan, Bruera, Equianalgesic Dose Ratios for Opioids: A Critical Review and Proposals for Long-Term Dosing, J. Pain Symptom Manag,
doi:10.1016/S0885-3924(01)00294-9Pierce, Bird, Hickman, Millar, National record linkage study of mortality for a large cohort of opioid users ascertained by drug treatment or criminal justice sources in England, 2005-2009, Drug Alcohol Depend,
doi:10.1016/j.drugalcdep.2014.09.782Ray, Chung, Murray, Hall, Stein, Prescription of Long-Acting Opioids and Mortality in Patients with Chronic Noncancer Pain, JAMA,
doi:10.1001/jama.2016.7789Schwetz, Calder, Rosenthal, Kattakuzhy, Fauci, Opioids and Infectious Diseases: A Converging Public Health Crisis, J. Infect. Dis,
doi:10.1093/infdis/jiz133Shah, Kuo, Baillargeon, Raji, The impact of long-term opioid use on the risk and severity of COVID-19, J. Opioid Manag,
doi:10.5055/jom.2020.0597Waghmare, Englund, Boeckh, How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation, Blood,
doi:10.1182/blood-2016-01-634873Wang, Kaelber, Xu, Volkow, COVID-19 risk and outcomes in patients with substance use disorders: Analyses from electronic health records in the United States, Mol. Psychiatry,
doi:10.1038/s41380-020-00880-7Weisberg, Gordon, Barry, Becker, Crystal et al., Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients, J. Acquir. Immune Defic. Syndr,
doi:10.1097/QAI.0000000000000591Wilson, Ramage, Fagan, A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder, J. Rural. Heal,
doi:10.1111/jrh.12438Wolfe, Caplan, Michaud, Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy, Arthritis Rheum,
doi:10.1002/art.21568{ 'indexed': {'date-parts': [[2022, 6, 3]], 'date-time': '2022-06-03T18:29:13Z', 'timestamp': 1654280953928},
'reference-count': 33,
'publisher': 'MDPI AG',
'issue': '13',
'license': [ { 'start': { 'date-parts': [[2021, 6, 24]],
'date-time': '2021-06-24T00:00:00Z',
'timestamp': 1624492800000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0/'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'abstract': '<jats:p>We aimed to investigate whether comorbid musculoskeletal disorders (MSD)s and pain '
'medication use was associated with in-hospital mortality among patients with coronavirus '
'disease 2019 (COVID-19). Adult patients (≥20 years old) with a positive COVID-19 diagnosis '
'until 5 June 2020 were included in this study, based on the National Health Insurance '
'COVID-19 database in South Korea. MSDs included osteoarthritis, neck pain, lower back pain, '
'rheumatoid arthritis, and others, while pain medication included paracetamol, gabapentin, '
'pregabalin, glucocorticoid, nonsteroidal anti-inflammatory drugs (NSAIDs), opioids (strong '
'and weak opioids), and benzodiazepine. Primary endpoint was in-hospital mortality. A total of '
'7713 patients with COVID-19 were included, and in-hospital mortality was observed in 248 '
'(3.2%) patients. In multivariate logistic regression analysis, no MSDs (p > 0.05) were '
'significantly associated with in-hospital mortality. However, in-hospital mortality was 12.73 '
'times higher in users of strong opioids (odds ratio: 12.73, 95% confidence interval: '
'2.44–16.64; p = 0.002), while use of paracetamol (p = 0.973), gabapentin or pregabalin (p = '
'0.424), glucocorticoid (p = 0.673), NSAIDs (p = 0.979), weak opioids (p = 0.876), and '
'benzodiazepine (p = 0.324) was not associated with in-hospital mortality. In South Korea, '
'underlying MSDs were not associated with increased in-hospital mortality among patients with '
'COVID-19. However, use of strong opioids was significantly associated with increased '
'in-hospital mortality among the patients.</jats:p>',
'DOI': '10.3390/ijerph18136804',
'type': 'journal-article',
'created': {'date-parts': [[2021, 6, 24]], 'date-time': '2021-06-24T15:01:38Z', 'timestamp': 1624546898000},
'page': '6804',
'source': 'Crossref',
'is-referenced-by-count': 5,
'title': 'Musculoskeletal Disorders, Pain Medication, and in-Hospital Mortality among Patients with '
'COVID-19 in South Korea: A Population-Based Cohort Study',
'prefix': '10.3390',
'volume': '18',
'author': [ {'given': 'Tak-Kyu', 'family': 'Oh', 'sequence': 'first', 'affiliation': []},
{'given': 'In-Ae', 'family': 'Song', 'sequence': 'additional', 'affiliation': []},
{'given': 'Joon', 'family': 'Lee', 'sequence': 'additional', 'affiliation': []},
{'given': 'Woosik', 'family': 'Eom', 'sequence': 'additional', 'affiliation': []},
{'given': 'Young-Tae', 'family': 'Jeon', 'sequence': 'additional', 'affiliation': []}],
'member': '1968',
'published-online': {'date-parts': [[2021, 6, 24]]},
'reference': [ {'key': 'ref1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)30673-5'},
{ 'key': 'ref2',
'unstructured': 'Dashboard by the Center for Systems Science and Engineering (CSSE) at '
'Johns Hopkins University (JHU). Global Map of Cases and Deaths by '
'Country/Region/Sovereigntyhttps://coronavirus.jhu.edu/map.html'},
{'key': 'ref3', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2101765'},
{'key': 'ref4', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)32623-4'},
{'key': 'ref5', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMc2009567'},
{'key': 'ref6', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41418-020-0530-3'},
{'key': 'ref7', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/ctr.13511'},
{'key': 'ref8', 'doi-asserted-by': 'publisher', 'DOI': '10.1182/blood-2016-01-634873'},
{'key': 'ref9', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciaa863'},
{'key': 'ref10', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.pain.2014.05.007'},
{'key': 'ref11', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/art.21568'},
{'key': 'ref12', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cmet.2016.10.010'},
{'key': 'ref13', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/ejp.1506'},
{'key': 'ref14', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.bja.2019.08.012'},
{'key': 'ref15', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s12020-020-02382-6'},
{'key': 'ref16', 'doi-asserted-by': 'publisher', 'DOI': '10.5055/jom.2020.0597'},
{ 'key': 'ref17',
'doi-asserted-by': 'publisher',
'DOI': '10.7326/0003-4819-147-8-200710160-00010'},
{'key': 'ref18', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0885-3924(01)00294-9'},
{ 'key': 'ref19',
'doi-asserted-by': 'publisher',
'DOI': '10.1093/oxfordjournals.aje.a009758'},
{'key': 'ref20', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.i1981'},
{'key': 'ref21', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2016.7789'},
{'key': 'ref22', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamanetworkopen.2018.0217'},
{'key': 'ref23', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.drugalcdep.2014.09.782'},
{'key': 'ref24', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/infdis/jiz133'},
{'key': 'ref25', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pmed.1003247'},
{'key': 'ref26', 'doi-asserted-by': 'publisher', 'DOI': '10.1097/QAI.0000000000000591'},
{'key': 'ref27', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/10826084.2020.1791184'},
{'key': 'ref28', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41380-020-00880-7'},
{'key': 'ref29', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jsat.2020.108153'},
{'key': 'ref30', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/jrh.12438'},
{'key': 'ref31', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2665-9913(20)30169-7'},
{'key': 'ref32', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/art.41456'},
{'key': 'ref33', 'doi-asserted-by': 'publisher', 'DOI': '10.2471/BLT.17.204891'}],
'container-title': 'International Journal of Environmental Research and Public Health',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.mdpi.com/1660-4601/18/13/6804/pdf',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2021, 6, 25]],
'date-time': '2021-06-25T09:09:46Z',
'timestamp': 1624612186000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.mdpi.com/1660-4601/18/13/6804'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021, 6, 24]]},
'references-count': 33,
'journal-issue': {'issue': '13', 'published-online': {'date-parts': [[2021, 7]]}},
'alternative-id': ['ijerph18136804'],
'URL': 'http://dx.doi.org/10.3390/ijerph18136804',
'relation': {},
'ISSN': ['1660-4601'],
'subject': ['Health, Toxicology and Mutagenesis', 'Public Health, Environmental and Occupational Health'],
'container-title-short': 'IJERPH',
'published': {'date-parts': [[2021, 6, 24]]}}
